Stocksigma LogoStocksigma Logo

Aarti Drugs Reports Strong Q2 FY27 Results with 83% YoY PAT Growth

Aarti Drugs reported a solid Q2 FY27 performance, with consolidated revenue rising 27% YoY to Rs. 828.8 crore. EBITDA surged 63% YoY to Rs

Aarti Drugs Reports Strong Q2 FY27 Results with 83% YoY PAT Growth

Aarti Drugs Ltd 路 Press Release 路 04 Nov 2026, 2:47 am

Aarti Drugs Reports Strong Q2 FY27 Results with 83% YoY PAT Growth Aarti Drugs reported a solid Q2 FY27 performance, with consolidated revenue rising 27% YoY to Rs. 828.8 crore. EBITDA surged 63% YoY to Rs. 137.9 crore, expanding margins by 370 bps to 16.6%. PAT jumped 83% YoY to Rs. 82.8 crore, driven by strong realisations across API, Formulations (+58% YoY to Rs. 130 crore), and Specialty Chemicals (+92% YoY to Rs. 71.8 crore). In H1 FY27, revenue grew 23% YoY to Rs. 1,532.4 crore, while PAT rose 34% YoY to Rs. 132.9 crore.

Original exchange filing (PDF)

More announcements from Aarti Drugs Ltd

All Aarti Drugs Ltd announcements